Cellectis Plant Sciences signs a license agreement, which allows it exclusive access to the University of Minnesota’s CRISPR technology.
The university grants Cellectis the worldwide rights to use the technology covered by the patent rights of the family WO/2014/144155 entitled “Engineering Plant Genomes Using CRISPR/Cas Systems.”
CRISPR technology enables a number of useful tools to target specific loci in a genome and modulate the expression of genes. The technology is based on novel sequence-specific nucleases that can be cheaply engineered to recognize any gene of interest in a genome. Application in plants, similarly to the other gene editing technologies, could enable the development of valuable crops.
The technology has demonstrated results in plant genome engineering and adds to Cellectis Plant Sciences’ strong intellectual property rights in the gene editing field, in addition to meganuclease and TALEN technologies, the company reports.
“We are pleased to strengthen our collaboration with the University of Minnesota and gain exclusive access to this technology that excites academics and the industrial community for its simple access to design new nucleases,” says Luc Mathis, Cellectis CEO. “CRISPR technology is being rapidly adopted by the life science community, and we are delighted to expand our technology portfolio to it, opening new opportunities for the commercial development of healthier food products.”
The university grants Cellectis the worldwide rights to use the technology covered by the patent rights of the family WO/2014/144155 entitled “Engineering Plant Genomes Using CRISPR/Cas Systems.”
CRISPR technology enables a number of useful tools to target specific loci in a genome and modulate the expression of genes. The technology is based on novel sequence-specific nucleases that can be cheaply engineered to recognize any gene of interest in a genome. Application in plants, similarly to the other gene editing technologies, could enable the development of valuable crops.
The technology has demonstrated results in plant genome engineering and adds to Cellectis Plant Sciences’ strong intellectual property rights in the gene editing field, in addition to meganuclease and TALEN technologies, the company reports.
“We are pleased to strengthen our collaboration with the University of Minnesota and gain exclusive access to this technology that excites academics and the industrial community for its simple access to design new nucleases,” says Luc Mathis, Cellectis CEO. “CRISPR technology is being rapidly adopted by the life science community, and we are delighted to expand our technology portfolio to it, opening new opportunities for the commercial development of healthier food products.”
Founded in 2010, Cellectis Plant Sciences has developed a platform to improve the quality of crops for the food and agriculture industries.
